ijms-logo

Journal Browser

Journal Browser

Glutamatergic Signaling in the Nervous System

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 20 September 2025 | Viewed by 1141

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Psychiatry and Psychology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054, USA
2. Department of Neuroscience, Mayo Clinic Graduate School of Biomedical Sciences, CRB, 03-031E, Scottsdale, AZ 85259, USA
Interests: brain imaging; substance use disorder; novel therapeutics; glutamatergic signaling; deep brain stimulation

Special Issue Information

Dear Colleagues,

The discovery of glutamate as a major excitatory neurotransmitter has sparked interest in understanding its role in physiological brain processes and how glutamatergic alterations can lead to various neurological and psychiatric disorders. The brain’s glutamate concentration is tightly regulated at every step, from neuronal synthesis to storage into vesicles, release into synaptic space, binding to different glutamatergic receptors, downstream signaling, uptake to astrocytes, conversion to glutamine, and shuttling glutamine back from astrocytes to neurons to produce glutamate again and repeat the cycle. Glutamatergic signaling intersects with cellular energy economy and with other critical processes, such as the labile iron pool and potentially ferroptosis. Current glutamatergic medications, such as ceftriaxone, riluzole, memantine, ketamine, topiramate, lamotrigine, N-acetylcysteine, and D-cycloserine, show efficacy in treating various disorders. However, other nodes along the glutamatergic signaling pathway and the intersecting pathways could theoretically provide potential targets for pharmacotherapy. This Special Issue aims to delve into the exciting world of glutamate and its intersecting pathways.

Dr. Osama Abulseoud
Prof. Dr. Frank Schmitz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glutamate glutamine cycle
  • neurotoxicty
  • ferroptosis
  • hyperglutamatergic states
  • innovative pharmacological interventions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1750 KiB  
Article
Dysbindin-1 Mutation Alters Prefrontal Cortex Extracellular Glutamate and Dopamine In Vivo
by Karen K. Szumlinski, Michael C. Datko, Kevin D. Lominac and J. David Jentsch
Int. J. Mol. Sci. 2024, 25(23), 12732; https://doi.org/10.3390/ijms252312732 - 27 Nov 2024
Viewed by 733
Abstract
Elevated risk for schizophrenia is associated with a variation in the DTNBP1 gene encoding dysbindin-1, which may underpin cognitive impairments in this prevalent neuropsychiatric disorder. The cognitive symptoms of schizophrenia involve anomalies in glutamate and dopamine signaling, particularly within the prefrontal cortex (PFC). [...] Read more.
Elevated risk for schizophrenia is associated with a variation in the DTNBP1 gene encoding dysbindin-1, which may underpin cognitive impairments in this prevalent neuropsychiatric disorder. The cognitive symptoms of schizophrenia involve anomalies in glutamate and dopamine signaling, particularly within the prefrontal cortex (PFC). Indeed, mice with Dtnbp1 mutations exhibit spatial and working memory deficits that are associated with deficits in glutamate release and NMDA receptor function as determined by slice electrophysiology. The present study extended the results from ex vivo approaches by examining how the Dtnbp1 mutation impacts high K+- and NMDA receptor-evoked glutamate release within the PFC using in vivo microdialysis procedures. Dntbp1 mutant mice are also reported to exhibit blunted K+-evoked dopamine release within the PFC. Thus, we examined also K+- and NMDA-evoked dopamine release within this region. Perfusion of high-concentration K+ or NMDA solutions increased the PFC levels of both dopamine and glutamate in wild-type (WT) but not in Dtnbp1 mutants (MUT), whereas mice heterozygous for the Dtnbp1 mutation (HET) exhibited blunted K+-evoked dopamine release. No net-flux microdialysis procedures confirmed elevated basal extracellular content of both glutamate and dopamine within the PFC of HET and MUT mice. These in vivo microdialysis results corroborate prior indications that Dtnbp1 mutations perturb evoked dopamine and glutamate release within the PFC, provide in vivo evidence for impaired NMDA receptor function within the PFC, and suggest that these neurochemical anomalies may be related to abnormally elevated basal neurotransmitter content. Full article
(This article belongs to the Special Issue Glutamatergic Signaling in the Nervous System)
Show Figures

Figure 1

Back to TopTop